Rapport Therapeutics’ Promising Trial Results and Leadership Change

An update from Rapport Therapeutics, Inc. ( (RAPP) ) is now available.

Rapport Therapeutics announced promising results from its PET and MAD-2 trials for RAP-219, a potential treatment for CNS disorders like focal epilepsy. The trials demonstrated that RAP-219 achieved target receptor occupancy within five days, maintained a favorable tolerability profile, and showed no sedation or motoric impairments. These findings support the dosing regimen for the ongoing Phase 2a trial in focal epilepsy, expected to report topline data in mid-2025. The announcement also noted a leadership change with the departure of Chief Medical Officer Bradley Galer, M.D.

More about Rapport Therapeutics, Inc.

Rapport Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing small molecule precision medicines for patients suffering from central nervous system (CNS) disorders. The company’s lead clinical program, RAP-219, is designed to achieve neuroanatomical specificity through selective targeting of receptor-associated proteins expressed in discrete brain regions, with ongoing clinical trials targeting focal epilepsy, diabetic peripheral neuropathic pain, and bipolar mania.

YTD Price Performance: -9.24%

Average Trading Volume: 106,649

Technical Sentiment Consensus Rating: Strong Buy

Current Market Cap: $610.5M

For an in-depth examination of RAPP stock, go to TipRanks’ Stock Analysis page.